Reuters: Global Markets: FDA extends review of Biogen MS drug; shares fall

Reuters: Global Markets Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

FDA extends review of Biogen MS drug; shares fall Oct 18th 2012, 13:07 Thu Oct 18, 2012 9:07am EDT (Reuters) - Biotechnology company Biogen Idec Inc said U.S. health regulators extended the review date of its multiple sclerosis drug, BG-12, by three months. Shares of Biogen were down 3 percent at $149.50 in premarket trading. The U.S. Food and Drug Administration needed additional time to review the application, the company said. The FDA did not ask for additional studies, Biogen said. The oral drug, also known as dimethyl fumarate, is currently under review by regulatory authorities in the European Union, Australia, Canada and Switzerland, apart from the United States.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions